Information Provided By: 
Fly News Breaks for January 23, 2017
ABT
Jan 23, 2017 | 07:41 EDT
Cowen analyst Joshua Jennings said Abbott's valuation is currently at a compelling discount, but that may not last long. He said the Abbott/St. Jude Medical combination has given him conviction the combined company can sustain greater than 5% organic growth and 12-15% earnings growth in 2018 to 2020. Jennings reiterated his Outperform rating and $48 price target on Abbott shares.
News For ABT From the Last 2 Days
